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CASE REPORT
A 66-year-old white female without a history of smoking pre-
sented with new onset chest discomfort and dyspnea. Chest 
imaging demonstrated a large left lower lobe mass, pleural 
deposits, and a left pleural effusion. Percutaneous biopsy 
(Fig. 1A) and pleural fluid analyses demonstrated adenocarci-
noma consistent with a lung primary (Fig. 2A, C, E, G, I). The 
patient received four cycles of carboplatin–pemetrexed with 
partial response. After two cycles of maintenance pemetrexed 
monotherapy, disease progression occurred. Molecular analy-
sis of the original biopsy demonstrated an activating exon 19 
EGFR mutation. Erlotinib was initiated with excellent clinical 
and radiographic response (Fig. 1B and C). Eight months later, 
the patient experienced disease progression. Repeat biopsy 
near the initial biopsy site (Fig. 1D) demonstrated squamous 
cell carcinoma (Fig. 2B, D, F, H, J) with persistent exon 19 
EGFR mutation (Fig. 3) and no evidence of T790M mutation. 
The patient’s functional status declined, and she developed 
paraneoplastic leukocytosis (WBC 73 × 103/mm) and hyper-
calcemia (calcium 12.5 mg/dL). She died shortly thereafter.
DISCUSSION
Despite initial efficacy, therapeutic resistance eventually 
emerges in essentially all cases of EGFR mutant non–small-
cell lung cancer treated with EGFR inhibitors. Described 
mechanisms include secondary EGFR resistance mutations 
(i.e., T790M; 49%), MET amplification or HGF overexpres-
sion (5%), upregulation of the Axl kinase (20–25%), PI3K 
pathway hyperactivation through PIK3CA mutation or PTEN 
loss (5%), epithelial-to-mesenchymal transition (40%), and 
histologic transformation to small-cell lung cancer (5–14%).1 
These rare cases of small cell transformation preserve the 
original sensitizing EGFR mutation, suggesting a monoclonal 
origin with the parent cells.
In this report, we describe the histologic transformation of 
EGFR mutant lung adenocarcinoma to squamous cell carcinoma 
as a mechanism of resistance to the EGFR inhibitor erlotinib. 
To our knowledge, only one similar case has been previously 
described.2 Potential explanations for this observation include 
that (1) malignant cells acquire a different phenotype under 
the pressure of EGFR inhibition (metaplastic transformation); 
(2) both types of cells coexist in the original tumor mass (i.e., 
adenosquamous histology, representing 5–10% of non–small-
cell lung cancer3), but only adenocarcinoma cells are sensitive 
to EGFR inhibition, giving selective advantage to the squamous 
cell component; or (3) development of a second primary cancer.
In this case, maintenance of the original EGFR mutation 
after histologic transformation makes the possibility of a second 
primary tumor unlikely. Instead, this phenomenon may indicate 
a population of pluripotent EGFR mutant cancer cells or cancer 
stem cells as the source of resistance.4 Although there are clear 
morphologic and immunohistochemical differences between the 
pretreatment and posttreatment specimens, the possibility of a 
mixed tumors cannot be ruled out because of the limited sampling 
provided by needle biopsies, even when performed in similar 
anatomic sites. We also acknowledge that the events in this case 
do not rule out the possibility that the pre-erlotinib chemotherapy 
may have played a role in selecting the squamous clone or driv-
ing alternative differentiation. Finally, our report is limited by the 
lack of additional tumor genomic analyses (e.g., MET, PIK3CA), 
which have been described in a minority of cases featuring small 
cell transformation after treatment with EGFR inhibitors.1
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FIGURE 2. A, Pre-erlotinib treatment core needle biopsy of left lower lobe lesion demonstrating epithelial cells with pleomor-
phic nuclei and a mucoid background (hematoxylin and eosin, 400×). B, Post-erlotinib treatment core needle biopsy showing 
epithelioid cells with vacuolated cytoplasm, pleomorphic nuclei with occasional prominent nucleoli, and intercellular bridges 
(hematoxylin and eosin, 600×). C, Positive nuclear staining for thyroid transcription factor-1 in the pretreatment (400×) and  
(D) negative in the posttreatment biopsy (200×). E, Positive cytoplasmic staining for Napsin A in the pretreatment (400×) and 
(F) negative in the posttreatment biopsy (200X). G, Negative staining for CK5/6 in the pretreatment (200×) and (H) positive 
stain in the posttreatment biopsy (200×). I, Negative staining for p63 in the pretreatment (200×) and (J) positive nuclear staining 
in the posttreatment core needle biopsy (200×).
FIGURE 1. A, computed tomogra-
phy (CT)-guided biopsy of the lung 
lesion at the time of diagnosis.  
B, chest CT before erlotinib admin-
istration. C, chest CT 3 months after 
erlotinib initiated. D, CT-guided 
biopsy of the lung cancer at the time 
of progression on erlotinib.
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FIGURE 3.  Colored peaks correspond to the exon 19 DNA sequence indicated as sample. The reference normal sequence is 
below. The 15 nucleotides deleted in the sample are underlined in the normal. The deletion appears homozygous.
